Funding for this research was provided by:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR064338-01A1)
Mick Hitchcock Scholarship
Received: 14 May 2020
Accepted: 17 May 2020
First Online: 4 June 2020
: All vertebrate animal studies described in this manuscript were performed under an animal protocol (#00404) approved by the University of Nevada, Reno IACUC.
: The University of Nevada, Reno, has a patent on the therapeutic use of laminin-111 and its derivatives. This patent has been licensed to Prothelia Inc., and the University of Nevada, Reno, has a small equity share in this company.